君實生物(688180.SH)：2021年實現營收40.25億元 同比增長152.36%
格隆匯3月31日丨君實生物(688180.SH)公佈2021年年度報吿，2021年公司實現營業收入40.25億元，同比增長152.36%。營業收入較去年同期增加約24.30億元，主要系本期技術許可收入的大幅增長、特許權收入的新增以及特瑞普利單抗注射液(商品名：拓益®)國內市場商業化帶來的銷售收入。
在創新藥研發方面，報吿期內公司繼續加大研發投入，研發費用達20.69億元，同比增長16.35%，有力地支撐了公司創新藥項目的研究與開發。截至報吿期末，公司擁有108項已授權專利，其中84項為境內專利，24項為境外專利。專利覆蓋新藥蛋白分子結構、製備工藝、用途、製劑配方等，為公司產品提供充分的和長生命週期的專利保護。
報吿期內，公司在研產品管線取得多項重要的研發進展。公司的創新研發領域已經從單抗藥物類型擴展至包括小分子藥物、多肽類藥物、抗體藥物偶聯物(ADCs)、雙特異性或多特異性抗體藥物、核酸類藥物等更多類型的藥物研發以及癌症、自身免疫性疾病的下一代創新療法探索。公司的在研產品管線覆蓋五大治療領域，包括惡性腫瘤、自身免疫系統疾病、慢性代謝類疾病、神經系統類疾病以及感染類疾病。
其中，處於商業化階段的在研產品共3項(特瑞普利單抗、埃特司韋單抗及阿達木單抗)，23項在研產品處於臨牀試驗階段(其中昂戈瑞西單抗、VV116、貝伐珠單抗以及PARP抑制劑處於III期臨牀試驗階段)，超過25項在研產品處在臨牀前開發階段。
報吿期內，公司在產品商業化、臨牀試驗、管線擴張方面取得了諸多重要進展，現金流情況良好，公司核心管理層及研發團隊穩定，吸引了大量優秀人才加入。隨着更多在研產品逐步實現商業化，特瑞普利單抗注射液更多適應症獲批並納入國家醫保目錄，公司的持續經營能力將不斷提升。
公司致力於創新療法的發現、開發和商業化。公司積極佈局覆蓋多項疾病治療領域的在研產品管線，未來仍將維持相應規模的研發投入用於在研產品進行臨牀前研究、全球範圍內的臨牀試驗以及新藥上市前準備等藥物開發工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
